Restricted accessResearch articleFirst published online 2014-06
Elimination of Human T Cell Leukemia Virus Type-1-Infected Cells by Neutralizing and Antibody-Dependent Cellular Cytotoxicity-Inducing Antibodies Against Human T Cell Leukemia Virus Type-1 Envelope gp46
Human T cell leukemia virus type-1 (HTLV-1) is prevalent worldwide with foci of high prevalence. However, to date no effective vaccine or drug against HTLV-1 infection has been developed. In efforts to define the role of antibodies in the control of HTLV-1 infection, we capitalized on the use of our previously defined anti-gp46 neutralizing monoclonal antibody (mAb) (clone LAT-27) and high titers of human anti-HTLV-1 IgG purified from HAM/TSP patients (HAM-IgG). LAT-27 and HAM-IgG completely blocked syncytium formation and T cell immortalization mediated by HTLV-1 in vitro. The addition of these antibodies to cultures of CD8+ T cell-depleted peripheral blood mononuclear cells (PBMCs) from HAM/TSP patients at the initiation of culture not only decreased the numbers of Tax-expressing cells and the production of HTLV-1 p24 but also inhibited the spontaneous immortalization of T cells. Coculture of in vitro-HTLV-1-immortalized T cell lines with autologous PBMCs in the presence of LAT-27 or HAM-IgG, but not an F(ab′)2 fragment of LAT-27 or nonneutralizing anti-gp46 mAbs, resulted in depletion of HTLV-1-infected cells. A 24-h 51Cr release assay showed the presence of significant antibody-dependent cellular cytotoxicity (ADCC) activity in LAT-27 and HAM-IgG, but not F(ab′)2 of LAT-27, resulting in the depletion of HTLV-1-infected T cells by autologous PBMCs. The depletion of natural killer (NK) cells from the effector PBMCs reduced this ADCC activity. Altogether, the present data demonstrate that the neutralizing and ADCC-inducing activities of anti-HTLV-1 antibodies are capable of reducing infection and eliminating HTLV-1-infected cells in the presence of autologous PBMCs.
Get full access to this article
View all access options for this article.
References
1.
PoieszBJ, RuscettiFW, ReitzMS, KalyanaramanVS, and GalloRC: Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature, 1981; 294(5838):268–271.
2.
HinumaY, NagataK, HanaokaM, et al.: Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA, 1981; 78(10):6476–6480.
3.
OsameM, UsukuK, IzumoS, et al.: HTLV-I associated myelopathy, a new clinical entity. Lancet, 1986; 1(8488):1031–1032.
4.
JacobsonS, RaineCS, MingioliES, and McFarlinDE: Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature, 1988; 331(6156):540–543.
5.
ProiettiFA, Carneiro-ProiettiAB, Catalan-SoaresBC, and MurphyEL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene, 2005; 24(39):6058–6068.
6.
IgakuraT, StinchcombeJC, GoonPK, et al.: Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science, 2003; 299(5613):1713–1716.
7.
Pais-CorreiaAM, SachseM, GuadagniniS, et al.: Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med, 2010; 16(1):83–89.
8.
KinoshitaT, ShimoyamaM, TobinaiK, et al.: Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc Natl Acad Sci USA, 1989; 86(14):5620–5624.
9.
HinumaY, GotohY, SugamuraK, et al.: A retrovirus associated with human adult T-cell leukemia: In vitro activation. Gann, 1982; 73(2):341–344.
10.
HanonE, HallS, TaylorGP, et al.: Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood, 2000; 95(4):1386–1392.
11.
GotohYI, SugamuraK, and HinumaY: Healthy carriers of a human retrovirus, adult T-cell leukemia virus (ATLV): Demonstration by clonal culture of ATLV-carrying T cells from peripheral blood. Proc Natl Acad Sci USA, 1982; 79(15):4780–4782.
12.
BaiXT and NicotC: Overview on HTLV-1 p12, p8, p30, p13: Accomplices in persistent infection and viral pathogenesis. Front Microbiol, 2012; 3:400.
13.
BanghamCR and OsameM: Cellular immune response to HTLV-1. Oncogene, 2005; 24(39):6035–6046.
14.
GoncalvesDU, ProiettiFA, RibasJG, et al.: Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev, 2010; 23(3):577–589.
15.
GessainA, GalloRC, and FranchiniG: Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol, 1992; 66(4):2288–2295.
16.
BonsignoriM, PollaraJ, MoodyMA, et al.: Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol, 2012; 86(21):11521–11532.
17.
MiyakoshiH, KoideH, and AokiT: In vitro antibody-dependent cellular cytotoxicity against human T-cell leukemia/lymphoma virus (HTLV)-producing cells. Int J Cancer, 1984; 33(3):287–291.
18.
SinclairAL, HabeshawJA, MuirL, et al.: Antibody-dependent cell-mediated cytotoxicity: Comparison between HTLV-I and HIV-1 assays. AIDS, 1988; 2(6):465–472.
19.
KozuruM, UikeN, TakeichiN, et al.: The possible mode of escape of adult T-cell leukaemia cells from antibody-dependent cellular cytotoxicity. Br J Haematol, 1989; 72(4):502–506.
20.
UnoH, KawanoK, MatsuokaH, and TsudaK: Natural killer activity and antibody-dependent cellular cytotoxicity in patients with adult T-cell leukemia. Nihon Ketsueki Gakkai Zasshi, 1989; 52(4):730–739.
21.
KunitomiT, TakigawaH, SugitaM, et al.: Antibody-dependent cellular cytotoxicity and natural killer activity against HTLV-1 infected cells. Acta Paediatr Jpn, 1990; 32(1):16–19.
22.
KurokiM, NakamuraM, ItoyamaY, et al.: Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1. J Immunol, 1992; 149(3):940–948.
23.
ZhangXQ, YangL, HoDD, et al.: Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: Strain specificity and epitope mapping. J Infect Dis, 1992; 165(5):805–812.
24.
KuoCW, MirsaliotisA, and BrightyDW: Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process. J Immunol, 2011; 187(1):361–371.
25.
SchneiderJ, YamamotoN, HinumaY, and HunsmannG: Sera from adult T-cell leukemia patients react with envelope and core polypeptides of adult T-cell leukemia virus. Virology, 1984; 132(1):1–11.
26.
LalRB: Delineation of immunodominant epitopes of human T-lymphotropic virus types I and II and their usefulness in developing serologic assays for detection of antibodies to HTLV-I and HTLV-II. J Acquir Immune Defic Syndr Hum Retrovirol, 1996; 13(Suppl 1):S170–178.
27.
HoralP, HallWW, SvennerholmB, et al.: Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc Natl Acad Sci USA, 1991; 88(13):5754–5758.
28.
TochikuraT, IwahashiM, MatsumotoT, KoyanagiY, HinumaY, and YamamotoN: Effect of human serum anti-HTLV antibodies on viral antigen induction in vitro cultured peripheral lymphocytes from adult T-cell leukemia patients and healthy virus carriers. Int J Cancer, 1985; 36(1):1–7.
29.
TanakaY, ZengL, ShirakiH, ShidaH, and TozawaH: Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol, 1991; 147(1):354–360.
30.
TanakaY, InoiT, TozawaH, YamamotoN, and HinumaY: A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). Int J Cancer, 1985; 36(5):549–555.
31.
TanakaY, LeeB, InoiT, TozawaH, YamamotoN, and HinumaY: Antigens related to three core proteins of HTLV-I (p24, p19 and p15) and their intracellular localizations, as defined by monoclonal antibodies. Int J Cancer, 1986; 37(1):35–42.
32.
TanakaY, YasumotoM, NyunoyaH, et al.: Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I). Int J Cancer, 1990; 46(4):675–681.
33.
InudohM, KatoN, and TanakaY: New monoclonal antibodies against a recombinant second envelope protein of hepatitis C virus. Microbiol Immunol, 1998; 42(12):875–877.
34.
TanakaR, TakahashiY, KodamaA, SaitoM, AnsariAA, and TanakaY: Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of beta-chemokines. AIDS Res Hum Retroviruses, 2010; 26(10):1147–1154.
35.
GillisS and WatsonJ: Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J Exp Med, 1980; 152(6):1709–1719.
36.
BabaE, NakamuraM, OhkumaK, et al.: A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. J Immunol, 1995; 154(1):399–412.
37.
TanakaY, TozawaH, KoyanagiY, and ShidaH: Recognition of human T cell leukemia virus type I (HTLV-I) gag and pX gene products by MHC-restricted cytotoxic T lymphocytes induced in rats against syngeneic HTLV-I-infected cells. J Immunol, 1990; 144(11):4202–4211.
38.
MelamedA, LaydonDJ, GilletNA, TanakaY, TaylorGP, and BanghamCR: Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog, 2013; 9(3):e1003271.
39.
TaniguchiY, NosakaK, YasunagaJ, et al.: Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology, 2005; 2:64.
SongES, YoungK, and SearsDW: Rat and human natural killers exhibit contrasting immunoglobulin G subclass specificities in antibody-dependent cellular cytotoxicity reflecting differences in their Fc receptors (Fc gamma R). J Leukoc Biol, 1990; 48(6):524–530.
42.
AckermanME, CrispinM, YuX, et al.: Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest, 2013; 123(5):2183–2192.
43.
LoKM, VivierE, RochetN, et al.: Infection of human natural killer (NK) cells with replication-defective human T cell leukemia virus type I provirus. Increased proliferative capacity and prolonged survival of functionally competent NK cells. J Immunol, 1992; 149(12):4101–4108.
44.
WeschD, MarxS, and KabelitzD: Monocyte-dependent death of freshly isolated T lymphocytes: Induction by phorbolester and mitogens and differential effects of catalase. J Immunol, 1998; 161(3):1248–1256.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
